Evidence map›Paper›PMID 41637016›Full record

ArticleMolecular diversity2026

Interpretable machine learning-driven identification of novel DENV NS2B-NS3 protease inhibitors through multi-stage virtual screening and experimental validation.

Shengjie Hu, Yan Xiao, Hailun Jiang, Peng Yao, Zhanchen Liu, Dahong Li, Yajun Liu, Maosheng Cheng

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shengjie Hu *Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, and Key Laboratory of Intelligent Drug Design and New Drug Discovery of Liaoning Province, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Yan Xiao *Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, and Key Laboratory of Intelligent Drug Design and New Drug Discovery of Liaoning Province, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Hailun JiangBeijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing, 100850, China.
Peng YaoKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, and Key Laboratory of Intelligent Drug Design and New Drug Discovery of Liaoning Province, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Zhanchen LiuKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, and Key Laboratory of Intelligent Drug Design and New Drug Discovery of Liaoning Province, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Dahong LiKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, and Key Laboratory of Intelligent Drug Design and New Drug Discovery of Liaoning Province, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Yajun LiuKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, and Key Laboratory of Intelligent Drug Design and New Drug Discovery of Liaoning Province, Shenyang Pharmaceutical University, Shenyang, 110016, China. liuyajun@syphu.edu.cn.
Maosheng ChengKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, and Key Laboratory of Intelligent Drug Design and New Drug Discovery of Liaoning Province, Shenyang Pharmaceutical University, Shenyang, 110016, China. mscheng@syphu.edu.cn.

Funding

‌Basic Scientific Research Project of Liaoning Provincial Department of Education LJ212510163009National Natural Science Foundation of China 22407093
6 · The paper itself

Abstract

Dengue fever is a mosquito-borne viral infection caused by dengue virus (DENV). It has emerged as a worldwide health problem, afflicting millions of people each year throughout the tropical and subtropical regions. To date, there is no FDA-approved drug for the treatment of dengue fever, highlighting the urgent need to discover novel anti-dengue drugs. In this study, multiple machine learning models were constructed to predict the inhibitory activity of small molecules against DENV NS2B-NS3, a protease that is crucial for the replication of DENV. Among them, RF-ECFP and XGBoost-ECFP were identified as the optimal models. The SHapley Additive exPlanations method was introduced for the interpretation of predictive results. Following the initial machine learning predictions, a multi-step screening process including multi-level molecular docking, molecular dynamics simulations, and molecular orbital calculations was conducted, ultimately identifying six hit compounds from a library containing ten million small molecules. Molecular docking indicated that compound 5 could form stable interactions with the catalytic triad in the active site of DENV NS2B-NS3 protease. The surface plasmon resonance and enzymatic inhibition assays further revealed that compound 5 exhibited a K

Indexed as

Antiviral AgentsDengue VirusMachine LearningProtease InhibitorsViral Nonstructural ProteinsCatalytic DomainDEAD-box RNA HelicasesDrug Evaluation, PreclinicalMolecular Docking SimulationMolecular Dynamics SimulationNucleoside-TriphosphataseRNA HelicasesSerine EndopeptidasesViral ProteasesAntiviral AgentsDEAD-box RNA Helicasesnonstructural protein 2B, Dengue virusNS2B protein, flavivirusNS3 protease, dengue virusNucleoside-TriphosphataseProtease InhibitorsRNA HelicasesSerine EndopeptidasesViral Nonstructural ProteinsViral ProteasesDengue feverMachine learningNS2B-NS3 proteaseSHAPVirtual screening

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.